Publisher Modification: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial

medicine

.Attribute Medication, Posted online: 16 Oct 2024 doi:10.1038/ s41591-024-03348-1Publisher Adjustment: Allogeneic CD5-specific CAR-T treatment for relapsed/refractory T-ALL: a phase 1 test.